Assenat E, Desseigne F, Thezenas S, Viret F, Mineur L, Kramar A, et al. Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trial. Oncologist. 2011;16:1557–64. https://doi.org/10.1634/theoncologist.2011-0141

Article  CAS  PubMed  PubMed Central  Google Scholar 

Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol J Am Soc Clin Oncol. 2007;25:1670–6. https://doi.org/10.1200/JCO.2006.09.0928

Article  CAS  Google Scholar 

Folprecht G, Hamann S, Schütte K, Trarbach T, Stoehlmacher-Williams J, Ehninger G. Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer. BMC Cancer. 2014;14:521 https://doi.org/10.1186/1471-2407-14-521

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fornaro L, Lonardi S, Masi G, Loupakis F, Bergamo F, Salvatore L, et al. FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). Ann Oncol J Eur Soc Med Oncol. 2013;24:2062–7. https://doi.org/10.1093/annonc/mdt165

Article  CAS  Google Scholar 

Garufi C, Torsello A, Tumolo S, Ettorre GM, Zeuli M, Campanella C, et al. Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial. Br J Cancer. 2010;103:1542–7. https://doi.org/10.1038/sj.bjc.6605940

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol J Am Soc Clin Oncol. 2009;27:672–80. https://doi.org/10.1200/JCO.2008.19.8135

Article  CAS  Google Scholar 

Masi G, Loupakis F, Salvatore L, Fornaro L, Cremolini C, Cupini S, et al. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol. 2010;11:845–52. https://doi.org/10.1016/S1470-2045(10)70175-3

Article  CAS  PubMed  Google Scholar 

Bajetta E, Celio L, Ferrario E, Di Bartolomeo M, Denaro A, Dotti K, et al. Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer. Ann Oncol J Eur Soc Med Oncol. 2007;18:1810–6. https://doi.org/10.1093/annonc/mdm347

Article  CAS  Google Scholar 

Souglakos J, Androulakis N, Syrigos K, Polyzos A, Ziras N, Athanasiadis A, et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer. 2006;94:798–805. https://doi.org/10.1038/sj.bjc.6603011

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stein A, Atanackovic D, Hildebrandt B, Stübs P, Brugger W, Hapke G, et al. Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer. Br J Cancer. 2015;113:872–7. https://doi.org/10.1038/bjc.2015.299

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJM, Schrama JG, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. New Engl J Med. 2009;360:563–72. https://doi.org/10.1056/NEJMoa0808268

Article  CAS  PubMed  Google Scholar 

Ychou M, Viret F, Kramar A, Desseigne F, Mitry E, Guimbaud R, et al. Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases. Cancer Chemother Pharm. 2008;62:195–201. https://doi.org/10.1007/s00280-007-0588-3

Article  CAS  Google Scholar 

Zarate R, Rodríguez J, Bandres E, Patiño-Garcia A, Ponz-Sarvise M, Viudez A, et al. Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis. Br J Cancer. 2010;102:987–94. https://doi.org/10.1038/sj.bjc.6605595

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bendell JC, Zakari A, Peyton JD, Boccia R, Moskowitz M, Gian V, et al. A phase II study of FOLFOXIRI plus panitumumab followed by evaluation for resection in patients with metastatic KRAS wild-type colorectal cancer with liver metastases only. Oncologist. 2016b;21:279–80. https://doi.org/10.1634/theoncologist.2015-0439

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bruera G, Santomaggio A, Cannita K, Baldi PL, Tudini M, De Galitiis F, et al. Poker” association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study. BMC Cancer. 2010;10:567 https://doi.org/10.1186/1471-2407-10-567

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gruenberger T, Bridgewater J, Chau I, García Alfonso P, Rivoire M, Mudan S, et al. Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial. Ann Oncol J Eur Soc Med Oncol. 2015;26:702–8. https://doi.org/10.1093/annonc/mdu580

Article  CAS  Google Scholar 

Hurwitz HI, Tan BR, Reeves JA, Xiong H, Somer B, Lenz H-J, et al. Phase II randomized trial of sequential or concurrent FOLFOXIRI-bevacizumab versus FOLFOX-bevacizumab for metastatic colorectal cancer (STEAM). Oncologist. 2019;24:921–32. https://doi.org/10.1634/theoncologist.2018-0344

Article  CAS  PubMed  Google Scholar 

Loupakis F, Cremolini C, Masi G, Lonardi S, Zagonel V, Salvatore L, et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. New Engl J Med. 2014;371:1609–18. https://doi.org/10.1056/NEJMoa1403108

Article  CAS  PubMed  Google Scholar 

Stein A, Glockzin G, Wienke A, Arnold D, Edelmann T, Hildebrandt B, et al. Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature. BMC Cancer. 2012;12:356 https://doi.org/10.1186/1471-2407-12-356

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cremolini C, Antoniotti C, Rossini D, Lonardi S, Loupakis F, Pietrantonio F, et al. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2020a;21:497–507. https://doi.org/10.1016/S1470-2045(19)30862-9

Article  CAS  PubMed  Google Scholar 

Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer: a personalized approach to clinical decision making. Ann Oncol J Eur Soc Med Oncol. 2012;23:2479–516. https://doi.org/10.1093/annonc/mds236

Article  CAS  Google Scholar 

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47. https://doi.org/10.1016/j.ejca.2008.10.026

Article  CAS  PubMed  Google Scholar 

Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol J Am Soc Clin Oncol. 2008;26:2013–9. https://doi.org/10.1200/JCO.2007.14.9930

Article  CAS  Google Scholar 

Sastre J, Vieitez JM, Gomez-España MA, Gil Calle S, Salud Salvia A, Suárez BG, et al. Randomized phase III study comparing FOLFOX + bevacizumab versus folfoxiri + bevacizumab (BEV) as 1st line treatment in patients with metastatic colorectal cancer (mCRC) with ≥3 baseline circulating tumor cells (bCTCs). J Clin Oncol. 2019;37:3507. https://doi.org/10.1200/JCO.2019.37.15_suppl.3507

Article  Google Scholar 

Bendell JC, Tan BR, Reeves JA, Xiong H, Somer BG, Lenz H-J, et al. Overall response rate (ORR) in STEAM, a randomized, open-label, phase 2 trial of sequential and concurrent FOLFOXIRI-bevacizumab (BEV) vs FOLFOX-BEV for the first-line (1L) treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol. 2016a;34:492. https://doi.org/10.1200/jco.2016.34.4_suppl.492

Article  Google Scholar 

Cremolini C, Antoniotti C, Stein A, Bendell J, Gruenberger T, Rossini D, et al. Individual patient data meta-analysis of FOLFOXIRI plus bevacizumab versus doublets plus bevacizumab as initial therapy of unresectable metastatic colorectal cancer. J Clin Oncol. 2020, https://doi.org/10.1200/JCO.20.01225.

Cremolini C, Loupakis F, Antoniotti C, Lupi C, Sensi E, Lonardi S, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 2015;16:1306–15. https://doi.org/10.1016/S1470-2045(15)00122-9

Article  CAS  PubMed  Google Scholar 

Vassilev Z, Fan X, Ostojic H, Xu J, Barzi A. Use of FOLFOXIRI plus bevacizumab in metastatic colorectal cancer (mCRC): An age-stratified analysis. J Clin Oncol. 2023;41:64 https://doi.org/10.1200/JCO.2023.41.4_suppl.64

Article  Google Scholar